title: No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics.
abstract: OBJECTIVE
  Although sexual dysfunction is believed to be caused by hormonal abnormalities, few reports have studied sexual dysfunction and its association with hormonal abnormalities in Asian populations with schizophrenia.
  
  
  METHODS
  We employed a cross-sectional, case-control survey design to collect data from 191 (108 men) Japanese schizophrenia outpatients treated with antipsychotics and 182 (49 men) healthy subjects. Sexual dysfunction was evaluated using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale. We measured plasma concentrations of prolactin in both genders and testosterone in men and estradiol in women.
  
  
  RESULTS
  Multiple regression analyses revealed the following findings: the number of antipsychotics correlated with diminished sexual desire (standardized beta = 0.241, p < 0.05); the dose of antipsychotics correlated with gynecomastia (standardized beta = 0.277, p < 0.01), increased sexual desire (standardized beta = 0.229, p < 0.05), and ejaculatory dysfunction (standardized beta = 0.248, p < 0.05); and the dose of antipsychotics correlated with menorrhagia in women (standardized beta = 0.284, p < 0.05). However, neither plasma concentrations of prolactin, testosterone nor estradiol correlated with sexual dysfunction.
  
  
  CONCLUSIONS
  The present study demonstrated that an association between sex hormone abnormalities and sexual dysfunction is unlikely but that the dose or number of antipsychotics is associated with some sexual dysfunction.
authors.affiliation: Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan. yasufuru@cc.hirosaki-u.ac.jp
authors.forename: Norio
authors.initials: N
authors.lastname: Yasui-Furukori
authors.forename: Akira
authors.initials: A
authors.lastname: Fujii
authors.forename: Norio
authors.initials: N
authors.lastname: Sugawara
authors.forename: Shoko
authors.initials: S
authors.lastname: Tsuchimine
authors.forename: Manabu
authors.initials: M
authors.lastname: Saito
authors.forename: Kojiro
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Sunao
authors.initials: S
authors.lastname: Kaneko
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People / Q000706:statistics & numerical data; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D012044:Regression Analysis; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012735:Sexual Dysfunction, Physiological / Q000453:epidemiology* / Q000209:etiology; D020018:Sexual Dysfunctions, Psychological / Q000453:epidemiology* / Q000209:etiology; D013739:Testosterone / Q000097:blood; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D013739:Testosterone; D004958:Estradiol; D011388:Prolactin